logo
  

Southwest Airlines Budgeted To Spend $1.3 Bln To Boost Efficacy

Southwest Airlines Inc. (LUV) said on Tuesday that it is budgeted to spend over $1.3 billion on investments, upgrades, and maintenance of information technology systems in 2023.

The investment serves as part of the airline's five-year Operational Modernization Plan which began prior to December 2022, with many initiatives already underway to further boost operational resiliency.

In December last year, strong winter storm had resulted in the cancellation of thousands of its flights during the long Christmas weekend.

Bob Jordan, Southwest's chief executive commented, "We understand the root causes that led to the holiday disruption, and we're validating our internal review with the third-party assessment. Now, we expect to mitigate the risk of an event of this magnitude ever happening again."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk's brain implant firm Neuralink said it has received approval from the U.S. Food and Drug Administration to conduct first-in-human clinical trials. In a tweet, Neuralink said, "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study! T.W. Garner Food Co. is recalling 50,688 bottles of 12 oz. Texas Pete Buffalo Wing Sauce citing undeclared soy, the U.S. Food and Drug Administration said. The agency noted that some of the bottles may contain Texas Pete Extra Mild Wing Sauce which contains soy. The recall involves Texas Pete Buffalo Wing Sauce with best used by 120623T 065239 UPC 0 75500 10011 6. The U.S. Food and Drug Administration approved Pfizer Inc's COVID-19 oral antiviral pill Paxlovid for the treatment of mild-to-moderate COVID-19 in adults. Paxlovid is the first oral treatment, and the fourth drug, approved by the agency to treat COVID-19 in adults. Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) has been approved to treat adults who are at high...
Follow RTT